EyePoint Pharmaceuticals’ stock (EYPT) surged on Monday after the company announced promising interim data from its Phase 2 VERONA trial of Duravyu for diabetic macular edema (DME). The data revealed that Duravyu 2.7mg demonstrated early, sustained, and clinically meaningful improvements in visual acuity and anatomical control compared to Eylea, a leading treatment for DME. This positive news has investors optimistic about the future of Duravyu as a potential new treatment option for DME.